Ibere Pharmaceuticals Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Vollmer Louis J., was filed 02 Mar 2021.
Ibere Pharmaceuticals: what insiders have been doing
Ibere Pharmaceuticals has a thin disclosure history in our data (latest filing: 2 March 2021). New filings will appear here as soon as they are published. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
- 10,000 shares@ US$10.00100.0% of flowUnitsSEC:0001104659-21-030721:0Canonical exit: 31 May 2021 (T+90)
1 of 1 declaration
About Ibere Pharmaceuticals
Ibere Pharmaceuticals is a NASDAQ-listed company focused on developing innovative pharmaceutical solutions. It specializes in research and commercialization of treatments for various diseases.
